Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...

With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...

Of the interviewed providers, 53.4% had experience with food allergy clinical trials, and 85% offered oral immunotherapy to ...

Topical delgocitinib appears more effective than oral alitretinoin and is comparable to dupilumab for treating types of hand eczema, according to two separate studies.

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Eli Lilly (NYSE:LLY) said it plans to take a Q3 acquired in-process research and development, or IPR&D, charge of ...

An industry group representing companies that manufactured the copycat versions of Eli Lilly's (NYSE:LLY) highly popular ...

Democratic Vice President Kamala Harris led Republican Donald Trump by a marginal three percentage points - 46% to 43% - as the two remain locked in a close race to win the Nov. 5 U.S ...

Israel’s air attacks against Hezbollah continued, and it said parts of a fourth military division had begun operating against the militant group in southwestern Lebanon. Much of Gaza has been de ...

Kamala Harris during a Tuesday appearance on “The View” is expected to announce a new policy aimed at helping families care for aging seniors. The vice president will propose establishing a ...